Gruberg Luis, Amikam Shlomo
Division of Invasive Cardiology, Rambam Medical Center, The Technion-Israel Institute of Technology, Haifa, Israel.
Int J Cardiovasc Intervent. 2003;5(2):92-4. doi: 10.1080/14628840304606.
Results from previous trials have shown conflicting results from local delivery of thrombolytic agents to diminish thrombus burden before intervention in native coronary arteries and saphenous vein grafts. We described a patient with an acute coronary syndrome who was treated for 24 hours with systemic tirofiban (Aggrastat), a glycoprotein IIb/IIIa inhibitor, for the treatment of a degenerated saphenous vein graft with a TIMI grade 4 thrombus (large-sized thrombus). Angiographic evaluation 48 hours later revealed complete resolution of the thrombus with normal coronary blood flow.
先前试验的结果显示，在对天然冠状动脉和隐静脉移植物进行干预前，局部递送溶栓剂以减轻血栓负荷的结果相互矛盾。我们描述了一名急性冠状动脉综合征患者，该患者使用糖蛋白IIb/IIIa抑制剂替罗非班（欣维宁）进行了24小时的全身治疗，以治疗一支TIMI 4级血栓（大尺寸血栓）的退化隐静脉移植物。48小时后的血管造影评估显示血栓完全溶解，冠状动脉血流正常。
